1. Falagas M.E., Kasiakou S.K.. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infection.
Clin Infect Dis 40:2005;1333–1341.
2. Li J., Nation R.L., Milne R.W., Turnidge J.D., Coulthard K.. Evaluation of colistin as an agent against multi-resistant gram-negative bacteria.
Int J Antimicrob Agents 25:2005;11–25.
3. Li J., Nation R.L., Turnidge J.D., Milne R.W., Coulthard K., Rayner C.R., Paterson D.L.. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infection.
Lancet Infect Dis 6:2006;589–601.
4. Biswas S., Brunel J.M., Dubus J.C., Reynaud-Gaubert M., Rolain J.M.. Colistin: an update on the antibiotics of the 21st century.
Expert Rev Anti Infect Ther 10:2012;917–934.
5. Ratjen F., Rietschel E., Kasel D., Schwiertz R., Starke K., Beier H., van Koningsbruggen S., Grasemann H.. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis.
J Antimicrob Chemother 57:2006;306–311.
6. Choi H.K., Kim Y.K., Kim H.Y., Uh Y.. Inhaled colistin for treatment of pneumonia due to colistin-only-susceptible
Acinetobacter baumannii.
Yonsei Med J 55:2014;118–125.
7. Kwa A.L., Loh C., Low J.G., Kurup A., Tam V.H.. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant
Acinetobacter baumannii and
Pseudomonas aeruginosa.
Clin Infect Dis 41:2005;754–757.
8. Levey A.S., Coresh J., Greene T., Marsh J., Stevens L.A., Kusek J.W., Van Lente F.. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values.
Clin Chem 53:2007;766–772.
9. Pintado V., San Miguel L.G., Grill F., Mejía B., Cobo J., Fortún J., Martín-Dávila P., Moreno S.. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria.
J Infect 56:2008;185–190.
10. Cheng C.Y., Sheng W.H., Wang J.T., Chen Y.C., Chang S.C.. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant gram-negative bacterial infections.
Int J Antimicrob Agents 35:2010;297–300.
11. Hartzell J.D., Neff R., Ake J., Howard R., Olson S., Paolino K., Vishnepolsky M., Weintrob A., Wortmann G.. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.
Clin Infect Dis 48:2009;1724–1728.
12. Akajagbor D.S., Wilson S.L., Shere-Wolfe K.D., Dakum P., Charurat M.E., Gilliam B.L.. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center.
Clin Infect Dis 57:2013;1300–1303.
13. Ordooei Javan A., Shokouhi S., Sahraei Z.. A review on colistin nephrotoxicity.
Eur J Clin Pharmacol 71:2015;801–810.
14. Macedo E., Mehta R.L.. Prerenal failure: from old concepts to new paradigms.
Curr Opin Crit Care 15:2009;467–473.
15. Blantz R.C., Singh P.. Analysis of the prerenal contributions to acute kidney injury.
Contrib Nephrol 174:2011;4–11.
16. Chronopoulos A., Rosner M.H., Cruz D.N., Ronco C.. Acute kidney injury in elderly intensive care patients: a review.
Intensive Care Med 36:2010;1454–1464.
17. Balkan I.I., Dogan M., Durdu B., Batirel A., Hakyemez I.N., Cetin B., Karabay O., Gonen I., Ozkan A.S., Uzun S., Demirkol M.E., Akbas S., Kacmaz A.B., Aras S., Mert A., Tabak F.. Colistin nephrotoxicity increases with age.
Scand J Infect Dis 46:2014;678–685.